肺栓塞患者直接口服抗凝药与其他药物的相互作用:Lungenembolie Augsburg(LEA)研究结果
该回顾性研究纳入477例肺栓塞患者,出院时记录用药并于3个月后复查,先用AiDKlinik®筛查药物相互作用,再用Lexicomp®核实机制。结果显示药物-抗凝相互作用与用药数量强相关(P<0.001)且呈非线性饱和效应;高血压患者发生至少一种药物-抗凝相互作用的OR为0.40(95%CI 0.17-0.96;P=0.040)。
要点
- 肺栓塞患者中DOAC与其他药物的相互作用随用药数量增加而增多,但呈非线性饱和效应。
- 高血压患者发生至少一种药物-抗凝相互作用的OR为0.40(95%CI 0.17-0.96;P=0.040)。
- 识别常见相互作用、风险因素及规避策略有助于优化DOAC治疗的安全性与有效性。
核心结论
- DOAC与其他药物的潜在相互作用是肺栓塞患者管理中的重要问题,需关注常见相互作用及风险因素以优化治疗。
研究设计与样本
- 回顾性研究,纳入477例肺栓塞患者,出院时记录用药并于3个月后复查。
- 使用临床决策支持系统AiDKlinik® Release 3.5初筛药物相互作用和药物相关问题,再将用药录入Lexicomp®获取详细机制与参考文献。
- 采用二元logistic随机截距模型识别药物-抗凝相互作用的潜在风险因素。
主要发现
- 纳入的477例肺栓塞患者中位用药数量为5种。
- 药物-抗凝相互作用强烈依赖用药数量(P值<0.001),但关联呈非线性,用药数量较多时出现饱和效应。
- 高血压患者发生至少一种药物-抗凝相互作用的OR为0.40(95%CI 0.17-0.96;P值=0.040)。
临床怎么用
- 对肺栓塞患者应系统筛查DOAC与其他药物的相互作用,尤其关注用药数量较多的患者。
- 可借助临床决策支持系统和综合药物相互作用数据库(如Lexicomp®)辅助识别相互作用及其机制。
- 了解常见相互作用、风险因素和规避策略,以优化DOAC治疗的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIM: Direct oral anticoagulants (DOACs) are now a well-established class of medication for blood clot prevention and treatment. So far, literature evaluating real-world data on the drug-drug interactions (DDIs) between DOACs and other medications in patients with pulmonary embolism (PE) is limited. This study aims to investigate these interactions in patients with PE to address this and improve patient care. MATERIALS AND METHODS: In a retrospective study, patients' medications were recorded upon hospital discharge and reviewed again 3 months later. A clinical decision support system (AiDKlinik® Release 3.5) was initially used to screen for DDIs and drug-related problems. Subsequently, medications were entered into Lexicomp®, a comprehensive drug interaction database, to gain detailed scientific explanations and references for the identified interactions and their mechanisms. Binary logistic random intercept models were used to identify potential risk factors of drug-anticoagulation interactions. RESULTS: The 477 included PE patients had a median intake of five drugs. Drug-anticoagulation interactions depended strongly on the number of medications taken (P value < 0.001). However, the association was non-linear, resulting in a saturation effect for a higher number of drugs. The odds ratio for having at least one drug-anticoagulation interaction was 0.40 (95% confidence interval 0.17-0.96; P value = 0.040) in patients with hypertension. CONCLUSIONS: The potential for DDIs with DOACs represents a significant concern. By being aware of the most common interactions, risk factors and avoidance strategies, the safety and efficacy of therapy can be optimized.
引用
- Schmelzer KP, Freuer D, Fischer S, et al. Drug-Drug Interactions Between Direct Oral Anticoagulants and Other Medications in Patients with Pulmonary Embolism: Results from the Lungenembolie Augsburg (LEA). Clin Pharmacokinet. 2025. PMID: 40782145. doi:10.1007/s40262-025-01556-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。